Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor α by Al-Dhaheri, Mariam H. & Rowan, Brian G.
Application of phosphorylation site-specific
antibodies to measure nuclear receptor signaling:
characterization of novel phosphoantibodies for
estrogen receptor α
Mariam H. Al-Dhaheri and Brian G. Rowan
Corresponding Author: browan@tulane.edu
Department of Biochemistry and Cancer Biology, Medical University of Ohio, Toledo, Ohio [MAD] and Department of Structural and Cellular Biology,
Tulane University School of Medicine and the Louisiana Cancer Research Consortium, New Orleans, Louisiana [BGR], USA
An understanding of posttranslational events in nuclear receptor signaling is crucial for drug design and
clinical therapeutic strategies. Phosphorylation is a well-characterized posttranslational modification that
regulates subcellular localization and function of nuclear receptors and coregulators. Although the role of
single phosphorylation sites in nuclear receptor function has been described, the contribution of combinations
of multiple phosphorylation sites to receptor function remains unclear.The development of phosphoantibodies
to each phosphorylation site in a nuclear receptor is a powerful tool to address the role of phosphorylation
in multiply phosphorylated receptors. However, phosphoantibodies must be rigorously validated prior to use.
This review describes the general methodology for design, characterization and validation of phosphoantibodies
using the example of eight phosphoantibodies raised against phosphorylation sites in estrogen receptor α
(ERα).
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Introduction
Phosphorylation is the well-established posttranslational
event that regulates subcellular localization, dimerization,
DNA binding, coregulator interaction and transcriptional
activity of nuclear receptors [Orti et al., 1992].
Understanding the role of phosphorylation in nuclear
receptor function is limited by receptor expression levels,
intracellular phosphatase activity, and low stoichiometry
and/or rapid turnover of some phosphorylation sites.
Several approaches may be used to study previously
identified phosphorylation sites in nuclear receptors
[Rowan et al., 2003]. Cells may be labeled in vivo with
32P orthophosphate followed by immunopurification and
phosphopeptide mapping. Similarly, purified receptor may
be phosphorylated in vitro with different kinases and
individual sites assessed by phosphopeptide mapping
[Rowan et al., 2003]. However these approaches are
labor intensive, time consuming, and require radioactive
material and large amounts of purified receptor. Mass
spectrometry is another approach to study protein
phosphorylation [Garcia et al., 2005].This
non-quantitative approach requires large amounts of
purified receptor and is limited primarily by costly
instrumentation and the need for a highly skilled operator.
The phosphoantibody approach to study receptor
phosphorylation overcomes several limitations inherent
in other approaches and provides the additional benefit
of allowing rapid assessment of combinations of receptor
phosphorylation sites by Western blotting [Rowan et al.,
2003].The advantages of the phosphoantibody approach
include: 1) a highly sensitive assay that can detect
phosphorylation in crude extracts containing low receptor
levels and/or low stoichiometry of phosphorylation without
the need for purified receptor; 2) the ability to profile total
receptor phosphorylation and to quantify relative levels
of each phosphorylation site; 3) immunoprecipitation of
receptors phosphorylated at specific sites to investigate
the recruitment of phosphoproteins to promoters
(chromatin immunoprecipitation (ChIP)) and to identify
phosphorylation sites involved in specific protein-protein
interaction (co-immunoprecipitation); 4) identification of
phosphorylation sites associated with real time dynamics
of receptor subcellular localization and recycling and other
cellular processes (immunofluorescence; flow cytometry
sorting); 5) the ability to monitor changes in the total
receptor phosphorylation profile during disease processes
such as the progression from benign to malignant cancer
(immunohistochemistry).
The phosphoantibody approach has been widely applied
to characterize nuclear receptor activity and subcellular
localization [Wang et al., 2002]. Glucocorticoid receptor
(GR) GR-P-S203 and GR-P-S211 phosphoantibodies
have been used by immunoblotting to study GR activation
by different ligands and by indirect immunofluorescence
to investigate the subcellular localization of the active
GR. Progesterone receptor (PR) phosphospecific
antibodies to sites S400 [Pierson-Mullany and Lange,
2004], S162, S190 and S294 [Narayanan et al., 2005]
were used by immunoblotting to study the ligand
independent activation of PR and to correlate PR
transcriptional activity and cell-cycle progression.
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was used by immunoblotting to study the mechanism of
ligand-dependent arrest of the AR in subnuclear foci
[Black et al., 2004]. Phosphoantibodies to ERα sites S118
and S167 [Chen et al., 2002; Shah and Rowan,
2005]were used by immunoblotting to study crosstalk
between ERα and several kinases. In addition, these
phosphoantibodies have been used by
immunohistochemistry to detect ERα phosphorylation in
human breast tumors [Murphy et al., 2004;Yamashita et
al., 2005].
The following section describes six key steps in
development and characterization of phosphoantibodies
to study nuclear receptor phosphorylation (Figure 1).The
first three steps include preparation, purification and initial
testing of phosphoantibodies and are generally performed
by commercial vendors.The remaining three steps to
validate and confirm specificity of the phosphoantibody
for specific phosphorylation sites are performed by the
investigator in the laboratory and are the major focus of
this review.
Peptide design and immunogen preparation
The synthetic phosphopeptide used for immunization is
recommended to be 10-20 amino acids in length and
conjugated with a suitable carrier that will solicit a strong
immune response and produce a large quantity of the
antibody [Eisele et al., 1999; Frank, 1984; Harlow and
Lane, 1988].The most widely used carriers in antibody
production are keyhole limpet hemacyanin (KLH) and
bovine serum albumin (BSA) [Harlow and Lane, 1988].
It is important to be aware of the conjugated carrier used
during immunization to anticipate any false positives that
may occur during antibody testing. For example if the
conjugated carrier is BSA, a false positive may arise if
BSA was used as a blocking agent for Western blotting.
Immunogenicity of the peptide-protein carrier can be
verified by an enzyme linked immunosorbent assay
(ELISA) to identify the most appropriate protein carrier
dose.
Producing hyper-immune serum
For broad specificity it is recommended that
phosphoantibodies be prepared as polyclonal antibodies
[Burns, 2005; Harlow and Lane, 1988; Leenaars and
Hendriksen, 2005; Lipman et al., 2005]. Rabbits are the
host of choice to avoid self-recognition of the immunogen
and since rabbits provide high amounts of sera.The
immunogen is mixed with adjuvant prior to immunizing
animals.
The immunogen mixture is injected subcutaneously and
re-administered at day 14 and 44 post immunization. At
day 54 sera is collected by bleeding of the marginal ear
vein. Bleeding is repeated on day 60 and then every 4
weeks until the antibody titer has declined. A booster
dose of immunogen should be administered to re-enhance
animal immunity and produce more sera [Burns, 2005].
After each bleeding, antibody titer should be measured
by ELISA.
Affinity Purification
Following harvest of the hyper-immune sera, the
phosphoantibody can be enriched by an affinity
purification against the phosphorylated peptide [Harlow
and Lane, 1988].The affinity purification is validated by
ELISA screening against the phosphopeptide in which
phosphoantibody purity should exceed 95%.Numerous
commercial suppliers will produce custom, affinity purified
phosphoantibodies (Bethyl Laboratories, Invitrogen,
Global Peptide, ABGENT, Open Biosystems and others).
Phosphoantibody specificity assessed by
receptor phosphorylation site mutations
Affinity purified phosphoantibody must be validated as
phosphorylation site specific. In mammalian cells that do
not express the receptor of interest, wild type receptor
expression plasmids or plasmids containing
phosphorylation site mutations (Serine (S) to Alanine (A),
Threonine (T) to A, Tyrosine (Y) to Phenylalanine (F))
should be transfected in cells to achieve high level protein
expression.Total cell extracts from wild-type and
phosphorylation site mutant transfected cells should be
prepared for Western blotting with the phosphoantibody
and peptide-competed phosphoantibody to assess
specificity for the phosphorylation site. High receptor
levels may be required to measure phosphorylation sites
that exhibit low stoichiometry. For other sites that require
an activation event, cells may first need to be incubated
with ligand, growth factor, kinase activator, etc. prior to
detection of the specific phosphorylation with a
phosphoantibody.
The ideal phosphoantibody should recognize receptor
from cells transfected with wild type but not the
site-specific mutant protein. However depending on cell
context, protein expression and stoichiometry, some
phosphoantibodies may fail to detect a signal in total
cellular extract. If this occurs, enrichment of receptor by
immunoprecipitation with a receptor-specific antibody is
recommended prior to Western blotting with the
phosphoantibody. It is critical that immunoprecipitation
be carried out over a brief period (no more than a few
hours) since dephosphorylation may occur over longer
periods. Regardless, phosphatase inhibitors should
always be included in lysis buffers whether receptor is
immunoprecipitated or not.
A critical step when first using phosphoantibodies for
Western blotting is to empirically determine the optimal
phosphoantibody concentration that will: 1) exhibit
reactivity with wild type, but not phosphorylation site
mutant receptor; and 2) not result in high general
background on Western blots. In our experience, some
phosphoantibodies exhibit specificity for wild type and
not phosphorylation site mutant receptor only at high
antibody dilutions.The appropriate antibody dilution must
be determined empirically using serial dilutions of the
affinity purified antibody in Western blot analysis.We
have found that some affinity purified phosphoantibodies
(stock concentration of 1 mg/ml) require dilution as high
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Methods Phosphoantibodies forERαFigure 1. Steps in phosphoantibody production and validation. Phosphopeptide design, rabbit immunization, phosphoantibody production and
affinity purification (steps 1-3) are performed by commercial vendors. Phosphoantibody specificity experiments (steps 4-6) are performed by the
investigator.
as 1:10,000 to eliminate non-specific reactivity with the
phosphorylation site mutant receptor.
Absence of phosphoantibody reactivity with
de-phosphorylated receptor
A second step for validation of phosphoantibodies is to
confirm the antibody does not react with receptor that has
been de-phosphorylated. In this context, the
hyper-phosphorylated form of the purified receptor should
be incubated in the presence or absence of λ
phosphatase, followed by Western blotting with the
phosphoantibody. Phosphatase treatment should prevent
reactivity of the phosphoantibody with the receptor.
in vitro receptor phosphorylation to measure
phosphoantibody reactivity
In some cell/tissue contexts that lack a specific kinase or
have inactive kinase, some phosphoantibodies may not
react with receptor due to absence or very low
stoichiometry of phosphorylation at a particular site. In
this scenario, in vitro phosphorylation of purified receptor
with a kinase known to phosphorylate the specific site
can be used prior to incubation with λ phosphatase.
Phosphoantibody reactivity with the purified protein should
increase following in vitro phosphorylation and signal
should be lost following λ phosphatase treatment. A
kinase that is not specific for the site in question should
be used as a control for the in vitro phosphorylation.
Reactivity and specificity: phosphoantibodies
to ERα as an example
In this study, phosphoantibodies developed against eight
different phosphorylation sites of ERα were characterized
(Figure 2). ERα is phosphorylated upon ligand binding
and/or crosstalk with kinases. Although there are eight
identified phosphorylation sites in ERα, (S104, S106,
S118, S167, S236, S305, T311, and Y537 [Lannigan,
2003; Michalides et al., 2004], only phosphoantibodies
against S118 and S167 have been widely applied for
receptor functional studies. Phosphoantibodies directed
against S104, S106 and Y537 are also commercially
available although application of these antibodies to
receptor functional studies is limited.This may be due to
lower stoichiometry of phosphorylation at these sites,
rapid turnover of tyrosine phosphorylation sites and/or
poorer affinity of these antibodies compared to the S118
and S167 phosphoantibodies.
Reagents
Antibodies
Bethyl Laboratories (Montgomery, TX) provided
complimentary phosphoantibodies: ERα ER-P-S104 (Cat.
# BL1637), ER-P-S106 (Cat. # BL1638), ER-P-S118 (Cat.
# BL1641), ER-P-S167 (Cat. # BL1643), ER-P-S236 (Cat.
# 1645), ER-P-S305 (Cat. # 1665), ER-P-T311 (Cat. #
BL1667) and ER-P-Y537 (Cat. # BL1647). Antibody D12
for ERα immunopreciptitation (Cat. # sc-8005) was
purchased from Santa Cruz Biotechnology (Santa Cruz,
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Methods Phosphoantibodies forERαFigure 2.  Schematic representation of ERα phosphorylation sites. ERα phosphorylation sites that have been confirmed in previous studies
by in vivo and/or in vitro phosphorylation are shown.
CA). ERα antibody clone 6F11 for Western blots of total
ERα (Cat. # VP-E613), peroxidase conjugated anti-mouse
(Cat. # π-2000) and peroxidase conjugated anti-rabbit
antibodies (Cat. # π-1000) were purchased from Vector
Laboratories (Burlingame, CA).
Purified ERα, phosphatase and kinases
Baculoviral expressed ERα (Cat. # P2187) was purchased
from Invitrogen (Carlsbad, CA). λ protein phosphatase
(Cat. # P0753S) and active recombinant full length human
CDK2-cyclin A complex expressed in E. coli (Cat. #
P6025S) were purchased from New England Biolabs
(Ipswich, MA). Baculoviral expressed, active recombinant
full length human protein kinase A (PKA) catalytic subunit
β (Cat. # PPK-448) was purchased from Stressgen (San
Diego, CA). Baculoviral expressed, active recombinant
full length human Src kinase (Cat. # 14-326) and active
recombinant human full length p38α/SAPK2a kinase
expressed in E. coli (Cat. # 14-587) were purchased from
Upstate (Charlottesville, VA).
Methods
Cell culture and transfection
COS-1 cells were maintained in DMEM phenol red free
medium containing 10% Fetal Bovine Serum (FBS), 2%
glutamine and 1% penicillin/streptomycin. Cells were
plated in 15 cm dishes for 48 hrs in DMEM phenol
red-free medium containing 5% FBS that was treated
with dextran-coated charcoal to remove endogenous
steroids.Wild type or phosphorylation site mutant ERα
constructs (6 μg) were transiently transfected in cells for
48 hrs using Fugene 6 (Roche, Indianapolis, IN). Cells
were incubated with 17β-estradiol (E2) (10 nM) or
Forskolin (10 µM) + IBMX (100 µM) (F/I) for 2 hrs. Cells
were harvested and cellular pellets were incubated in
high salt lysis buffer (10 mM Tris pH 8.0, 0.4 M NaCl, 2
mM EDTA pH 8.0, 2 mM EGTA, 10 mM
β-mercaptoethanol, 0.1% Triton X100, 1 mM sodium
orthovanadate, 20 mM β-glycerophosphate, 25 mM
sodium fluoride, 0.1 mM PMSF) containing protease
inhibitor mixture (σ, St. Louis, MO) for 10 min in ice.
Immunoprecipitation of ERα
Protein A sepharose beads (Amersham Biosciences,
Piscataway, NJ) were re-swelled in phosphate buffer
saline (PBS) and incubated with ERα antibody (D12,
Santa Cruz) by rotating the beads at room temperature
for 2 hrs. Beads were washed three times with PBS,
followed by incubation with the total COS-1 cellular extract
for 3 hrs at 4 C with rotation. Beads were washed three
times with PBS, followed by addition of 5X SDS-PAGE
loading buffer. Beads were incubated at 100 C for 5 min
to elute ERα. Samples were electrophoresed by
SDS-PAGE and phosphorylation of ERα was detected
by Western blotting using site specific phosphoantibodies.
Phosphoantibody signals obtained by Kodak Image
analysis of Western blots were normalized to total ERα
level by incubating the membrane in stripping buffer (2%
SDS, 100 mM β-mercaptoethanol, 62.5 mM Tris HCl pH
6.8) at 55 C for 30 min with rotation and re-probing the
membrane by Western blot with antibody against total
ERα (clone 6F11, Vector Laboratories).
λ Phosphatase analysis
200 ng purified ERα was incubated with 200ng λ
phosphatase in reaction buffer (50mM Tris-HCl, 100 mM
NaCl, 2 mM MnCl2 2mM dithiothreitol (DTT), 0.1 mM
EGTA, 0.01 % Brij 35, pH 7.5) for 1 hr at 30 C.To
terminate the reaction, 5X SDS-PAGE loading buffer was
added and samples were incubated at 100 C for 5 min.,
followed by SDS-PAGE and Western blots using site
specific phosphoantibodies
in vitro phosphorylation
Purified ERα (200 ng) was incubated with the site specific
kinase or kinase complex, ATP, and kinase buffer for 1
hr at 30 C in the presence or absence of λ phosphatase.
Kinases used were: CDK2-cyclin A (100 ng; (kinase buffer
50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT,
0.01% Brij 35, pH 7.5); PKA (100 ng) or inactive PKA
(PKA incubated at 100 C for 2 min.; kinase buffer (20 mM
MOPS pH 7.0, 1 mM sodium orthovanadate, 25 mM
β-glycerophosphate, 1 mM EGTA, 1 mM DTT, 7 mM
MgCl2); P38α/SAPK2a (100 ng; (kinase buffer 25 mM
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ng; kinase buffer 8 mM MOPS pH 7.0, 0.2 mM EDTA).
in vitro phosphorylation reactions were terminated by
addition of 5X SDS-PAGE loading buffer and incubation
of samples at 100 C for 5 min. Following SDS-PAGE,
phosphorylation of S104, S236, S305, T311, and Y537
were detected by Western blotting with
phosphoantibodies.
Results
The initial step for characterization of phosphoantibodies
is to prove the antibody is site specific. For this purpose,
wild type ERα and site mutant ERα constructs were
separately transfected into ERα-negative COS-1 cells.
Cells were then incubated with 17β-estradiol (10-8M) or
forskolin (10µM) + IBMX (100µM) for 2 hrs and cell
extracts were prepared for Western blotting.
Phosphorylation sites with low stoichiometry or antibodies
with low affinity may not detect receptor in crude cellular
extracts. For this reason ERα was first
immunoprecipitated with a separate ERα antibody (D12,
Santa Cruz) and then the immunopurified receptor was
subjected to Western blotting with the phosphoantibodies.
Phosphoantibodies to ERα-P-S104 (Figure 3A),
ERα-P-S106 (Figure 3B), ERα-P-S118 (Figure 3C),
ERα-P-S167 (Figure 3D), ERα-P-S236 (Figure 3E),
ERα-P-S305 (Figure 3F), ERα-P-T311 (Figure 3G) and
ERα-P-Y537 (Figure 3H) detected wild type ERα, but not
phosphorylation site ERα mutants, indicating that
antibodies were site specific. For some
phosphoantibodies serial dilutions were prepared to
determine the optimal antibody concentration for detection
of wild type, but not mutant ERα. At high concentration
(2 μg/ml) the ERα-P-S167 phosphoantibody recognized
both wild-type ERα and mutant S167A (data not shown).
This nonspecific interaction with mutant S167A was
absent when the antibody concentration was decreased
to 0.25 μg/ml (Figure 3D).
Specificity of the antibodies was verified by λ phosphatase
treatment of the hyper-phosphorylated purified ERα or
by in vitro phosphorylation of ERα with specific kinases.
Phosphoantibodies to sites S106, S118 and S167
recognized purified, baculoviral expressed ERα, indicating
that kinase pathways that phosphorylate these sites are
conserved in insect Sf9 cells (Figure 4 A-C, lane 1). A
similar conservation between mammalian and Sf9 insect
cells for receptor phosphorylation was observed with
baculoviral expressed progesterone receptor [Beck et al.,
1996]. Purified ERα was incubated with λ phosphatase
for 1 hr at 30 C and the phosphorylation of S106, S118,
and S167 was assessed by Western blotting with the
phosphospecific antibodies. λ phosphatase treatment of
ERα resulted in loss of Western blot signal with
phosphoantibodies to sites S106 (Figure 4A), S118
(Figure 4B) and S167 (Figure 4C).
Unlike phosphoantibodies to S106, S118, and S167,
phosphoantibodies to sites S104, S236, S305, T311 and
Y537 exhibited no reactivity with purified ERα (data not
shown).The antibody specificity was assessed by in vitro
phosphorylation of ERα with CDK2-cyclin A, PKA,
p38α/SAPK2a and Src kinases followed by Western
blotting with phosphoantibodies to sites S236, S305, T311
and Y537.
CDK2-cyclin A significantly induced the phosphorylation
of site S104 (Figure 5A, lane 2) and subsequent λ
phosphatase treatment (Figure 5A, lane 3) abolished the
phosphorylation as assessed by Western blotting with
the ERα-P-S104 phosphoantibody. In the absence of
kinase, incubation of purified baculoviral ERα with kinase
buffer and ATP also resulted in phosphorylation of site
S104 (Figure 5A, lane 1), suggesting that purified,
baculoviral ERα may be contaminated with a co-purifying
kinase.
Incubation of ERα with active PKA, but not inactive PKA,
resulted in phosphorylation of ERα at S236 (Figure 5B,
lane 2 versus lane 1) and S305 (Figure 5C, lane 2 versus
lane 1). in vitro phosphorylation of ERα with
P38α/SAPK2a complex resulted in T311 phosphorylation
(Figure 5D, lane 3), and this phosphorylation was lost
with subsequent λ phosphatase incubation (Figure 5D,
lane 2). Incubation of ERα with Src kinase resulted in
phosphorylation of ERα at Y537 (Figure 5E, lane 2) and
this phosphorylation was markedly reduced with
subsequent λ phosphatase incubation (Figure 5E, lane
3).
Discussion
Although there are several different methods to
characterize changes in receptor phosphorylation, the
phosphoantibody approach is particularly useful for
simultaneously measuring each phosphorylation site. In
this report the general steps in characterizing and
validating phosphoantibodies are described using the
example of phosphoantibodies raised against eight
phosphorylation sites in ERα.Validation of each
phosphoantibody was assessed in two steps; first the site
specificity of the phosphoantibody was validated by
expressing ERα wild type or site mutant plasmids into
receptor negative cell lines. Second, the phosphoantibody
specificity was validated by incubating the
hyper-phosphorylated purified ERα with λ phosphatase
and by performing in vitro phosphorylation with a specific
kinase or kinase complex that is known to phosphorylate
a specific site.
Although all eight phosphoantibodies raised against each
ERα phosphorylation site were site specific, these
phosphoantibodies reacted differently with the
hyper-phosphorylated, baculoviral expressed ERα. Only
phosphoantibodies to sites S106, S118 and S167
recognized the baculoviral expressed ERα.This may
have occurred because some sites are not
phosphorylated in insect Sf9 cells due to either the
absence of kinase activity or the presence of
phosphatases that prevent ERα phosphorylation at these
sites.
CDK2-cyclin A is a specific kinase complex previously
shown to phosphorylate both S104 and S106 of ERα
[Rogatsky et al., 1999]. Because of the close proximity
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Methods Phosphoantibodies forERαFigure 3.  Immunoprecipitation of wild type and mutant ERα and Western blotting with phosphoantibodies. COS-1 cells were plated in
DMEM media containing 5% FBS treated with charcoal coated dextran to remove the endogenous steroids. Cells were transfected with wild type ERα
(A-H) or ERα phosphorylation site mutants ERαS104A (A), ERαS106A (B), ERαS118A (C), ERαS167A (D), ERαS236A (E), ERαS305A (F), ERαT311A
(G), or ERαY537A (H). Cells were incubated with 17β-estradiol (A-D, G, H) or F/I (E, F) for 2 hrs, followed by preparation of cell extracts for
immunoprecipitation.Total ERα was immunoprecipitated with ERα antibody (D12, Santa Cruz) and phosphorylation of ERα was detected by Western
blot using site specific phosphoantibodies.The immunoblot was stripped and re-probed by Western blot with antibody to total ERα (Clone 6F11, Vector
Laboratories).
Figure 4.  Phosphatase treatment of purified ERα and Western blotting with phosphoantibodies. Purified ERα (200ng) was incubated in the
presence or absence of phosphatase λ (200ng) at 30 °C for 1 hr and phosphorylation of ERα was detected by Western blotting using ERα-P-S106 (A),
ERα-P-S118 (B), or ERα-P-S167 (C) phosphoantibodies.
of S104 and S106, it is possible that phosphorylation of
one site may be required for phosphorylation of the
adjacent site (currently under investigation). Serine 236
and Serine 305 are located within consensus sequences
for PKA and phosphorylation of these sites by PKA has
been demonstrated [Chen et al., 1999; Michalides et al.,
2004].The direct kinase that phosphorylates ERα at T311
has not been identified. Lee and Bai [Lee and Bai, 2002]
reported that T311 is phosphorylated by a p38 MAPK
kinase complex that contained both p38α and SAPK2a.
Since T311 does not lie within a consensus sequence for
MAPK phosphorylation (the T residue is not followed by
a proline residue), it is highly unlikely that p38 directly
phosphorylates T311. A more likely explanation is that
the kinase that directly phosphorylates T311 is a kinase
that copurified with p38 in the present and previous study.
Y537 is present within a Src kinase consensus sequence
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Methods Phosphoantibodies forERαFigure 5. in vitro phosphorylation of purified ERα and Western blotting with phosphoantibodies. Purified ERα (200 ng) was incubated with
or without CDK2-cyclin A complex (100 ng) (A), PKA (100 ng) (B, C), P38α/SAPK2a complex (100 ng) (D), or Src (100 ng) (E) in the presence or
absence of λ phosphatase (200 ng) (A, D, E) for 1 hr at 30°C. PKA was inactivated by incubating the kinase at 100°C for 2 min. ERα phosphorylation
was detected by Western blot analysis using ERα-P-S104 (A), ERα-P-S236 (B), ERα-P-S305 (C), ERα-P-T311 (D), or ERα-P-Y537 (E) phosphoantibodies.
and is phosphorylated by Src kinase in vitro [Arnold and
Notides, 1995; Arnold et al., 1995].
In summary, development of phosphoantibodies to assess
the functional role of nuclear receptor phosphorylation is
a powerful approach that has distinct advantages over
other more labor intensive and costly approaches.
However, rigorous validation experiments must precede
use of phosphoantibodies to ascertain both reactivity with
the phosphorylated receptor and absence of cross
reactivity with non-phosphorylated receptor.
Phosphoantibody specificity is determined using several
complimentary approaches, including expression of wild
type and mutant receptor in cells, phosphatase treatment
of receptor, and in vitro phosphorylation of receptor. Using
phosphoantibodies that are specific for each identified
phosphorylation site will permit investigators to
simultaneously measure the entire profile of receptor
phosphorylation during studies that probe nuclear receptor
mechanisms of action.
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